Harrow (HROW) Q4 Earnings and Revenues Top Estimates

Core Viewpoint - Harrow (HROW) reported quarterly earnings of $0.25 per share, significantly exceeding the Zacks Consensus Estimate of $0.11 per share, and showing a turnaround from a loss of $0.27 per share a year ago, indicating a strong performance in the recent quarter [1][2] Financial Performance - The company achieved revenues of $66.83 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.24%, and showing a substantial increase from $36.36 million in the same quarter last year [2] - Over the last four quarters, Harrow has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Harrow shares have declined approximately 17.6% since the beginning of the year, contrasting with the S&P 500's decline of 2.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $64.33 million, while for the current fiscal year, the estimate is $0.54 on revenues of $294.58 million [7] - The trend of estimate revisions for Harrow is mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Harrow belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]